CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
19 hedge funds and large institutions have $8.17M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
26% less capital invested
Capital invested by funds: $11M → $8.17M (-$2.81M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$752K | |
| 2 | +$460K | |
| 3 | +$305K | |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$262K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$112K |
Top Sellers
| 1 | -$3.72M | |
| 2 | -$317K | |
| 3 | -$138K | |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$134K |
| 5 |
Citigroup
New York
|
-$32K |